The 38 most recent market catalysts affecting $RARE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18
Evercore ISI Group analyst Liisa Bayko reiterated an 'In-Line' rating for Ultragenyx Pharmaceutical (RARE) but raised the price target from $16 to $18. This action suggests that wh…
Sep 21, 2026
Market Technicals
Bullish
Impact 55
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35
Barclays analyst Eliana Merle reiterated an 'Overweight' rating on Ultragenyx Pharmaceutical (RARE) and raised the price target from $32 to $35. This action signals continued confi…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20
Morgan Stanley analyst Maxwell Skor maintained an 'Equal-Weight' rating on Ultragenyx Pharmaceutical (RARE) while raising the price target from $18 to $20. This action signals a mo…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39
Canaccord Genuity's analyst Whitney Ijem has maintained a 'Buy' rating on Ultragenyx Pharmaceutical (RARE) and raised the price target from $37 to $39. This indicates a positive ou…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 85
Ultragenyx Pharmaceutical Says FDA Grants Standard Full Approval Of FAYUVI For Treatment Of Pediatric Patients With Mucopolysaccharidosis Type IIIA
Ultragenyx Pharmaceutical (RARE) announced the full FDA approval of FAYUVI for pediatric Sanfilippo syndrome Type A, a progressive and fatal neurodegenerative disease. This is a ma…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $39
Cantor Fitzgerald analyst Kristen Kluska has maintained an 'Overweight' rating on Ultragenyx Pharmaceutical (RARE) and raised the price target from $33 to $39. This upward revision…
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 95
Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending
Ultragenyx Pharmaceutical (RARE) experienced a significant stock surge following the FDA's full approval of FAYUVI, a groundbreaking gene therapy for Sanfilippo syndrome Type A. Th…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 75
Ultragenyx Pharmaceutical Exec Says U.S. Per Patient Wholesale Acquisition Cost For Fayuvi Is Set At $3.95M
Ultragenyx Pharmaceutical has disclosed the U.S. wholesale acquisition cost for its drug Fayuvi at $3.95 million per patient. This is a significant event as it establishes the reve…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 85
Ultragenyx Pharmaceutical shares are trading higher after the company announced the FDA approval of FAYUVI for treatment of pediatric patients with mucopolysaccharidosis type IIIA.
This FDA approval is a major positive catalyst for Ultragenyx Pharmaceutical, as it signifies a successful culmination of years of research and development for a rare disease treat…
Sep 4, 2026
Corporate Catalyst
Bearish
Impact 60
Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $19
Goldman Sachs analyst Salveen Richter maintained a 'Neutral' rating on Ultragenyx Pharmaceutical (RARE) but reduced the price target from $28 to $19. This 32% reduction in the pric…
Sep 4, 2026
Corporate Catalyst
Bearish
Impact 65
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32
Barclays analyst Eliana Merle maintained an 'Overweight' rating on Ultragenyx Pharmaceutical (RARE) but lowered the price target from $43 to $32. This action signals that while Bar…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 75
JP Morgan Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $36
JP Morgan's downgrade of Ultragenyx Pharmaceutical (RARE) from Overweight to Neutral, coupled with a drastic reduction in its price target from $80 to $36, signals a significant sh…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 85
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target
Ultragenyx (RARE) faces significant headwinds after its Phase 3 Aspire study failed, leading to planned cost-cutting and substantial analyst downgrades, with price targets slashed …
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 75
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $18
Wells Fargo analyst Benjamin Burnett has maintained an 'Overweight' rating on Ultragenyx Pharmaceutical but drastically cut the price target from $50 to $18. This action indicates …
Sep 3, 2026
Macro/Central Bank
Bullish
Impact 65
Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher
This filing provides a snapshot of market activity, highlighting a general upward trend in US equities, particularly the Nasdaq, despite slightly higher-than-expected jobless claim…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $23
Wedbush analyst Laura Chico has reiterated a Neutral rating on Ultragenyx Pharmaceutical (RARE) but has reduced the price target from $30 to $23. This 23% reduction in the price ta…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 95
Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results
Ultragenyx's Phase 3 trial for apazunersen, a key pipeline asset for Angelman syndrome, failed to meet its primary and secondary endpoints. This is a major blow to the company's dr…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 65
This Sonoco Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
The filing reports multiple analyst downgrades across three companies: Sonoco Products (SON), Ultragenyx Pharmaceutical (RARE), and Moderna (MRNA). For SON and RARE, the downgrades…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 65
Evercore ISI Group Downgrades Ultragenyx Pharmaceutical to In-Line, Lowers Price Target to $16
Evercore ISI Group's downgrade of Ultragenyx Pharmaceutical (RARE) from Outperform to In-Line, coupled with a drastic reduction in its price target from $34 to $16, signals a signi…
Sep 3, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Thursday's Pre-Market Session
This Benzinga article, presented as an 8-K filing, details the pre-market performance of 12 healthcare stocks. The movements are quite dramatic, with Gelteq and bioAffinity Technol…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 95
Ultragenyx Pharmaceutical shares are trading lower after the company announced results from the Phase 3 Aspire study for apazunersen did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index.
The failure of a Phase 3 clinical trial is a major negative catalyst for any pharmaceutical company, especially for a drug that was likely a significant part of its future growth s…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 75
Baird Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $16
Baird's downgrade of Ultragenyx Pharmaceutical (RARE) from Outperform to Neutral, coupled with a drastic reduction in its price target from $40 to $16, signals a significant shift …
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 65
Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $33
Cantor Fitzgerald analyst Kristen Kluska has significantly reduced the price target for Ultragenyx Pharmaceutical (RARE) from $103 to $33, a substantial cut of approximately 68%. D…
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 95
Ultragenyx Pharmaceutical shares are trading lower after the company announced results from the Phase 3 Aspire study for apazunersen did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index.
The failure of a Phase 3 clinical trial is a major negative catalyst for any pharmaceutical company, especially when it involves a drug that was expected to be a significant revenu…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 65
Ultragenyx FDA-Approved Treatment Shows Sustained Reduction in Cornstarch Intake
Ultragenyx (RARE) has published 96-week Phase 3 data for its gene therapy GENGLYCOS (DTX401), showing sustained efficacy and safety in GSDIa patients. This is significant because t…
Sep 1, 2026
Corporate Catalyst
Bearish
Impact 85
Ultragenyx Says Week 96 Phase 3 Data On GENGLYCOS In Glycogen Storage Disease Type Ia Show 61% Mean Reduction In Daily Cornstarch Intake, With 33% Of Treatment Group And 42% Of Crossover Group Eliminating Nighttime Dosing
This headline represents a significant corporate catalyst for Ultragenyx (RARE). The impressive Phase 3 data for GENGLYCOS, particularly the 61% mean reduction in daily cornstarch …
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 60
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $50
Wells Fargo analyst Michael Turrin maintained an 'Overweight' rating on Ultragenyx Pharmaceutical (RARE) and raised the price target from $46 to $50. This action signals continued …
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $80
This filing discloses that JP Morgan, a prominent investment bank, has raised its price target for Ultragenyx Pharmaceutical (RARE) from $75 to $80 while maintaining an 'Overweight…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $74
Morgan Stanley analyst Jeffrey Hung has maintained an Overweight rating on Ultragenyx Pharmaceutical (RARE) and raised the price target from $67 to $74. This indicates a strengthen…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $58
Citigroup analyst Yigal Nochomovitz has maintained a 'Buy' rating on Ultragenyx Pharmaceutical (RARE) and raised the price target from $45 to $58. This action signals increased con…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $46
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on Ultragenyx Pharmaceutical (RARE) and raised the price target from $45 to $46. This action signals continue…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 92
Ultragenyx Nabs FDA Nod for First Gene Therapy
Ultragenyx Pharmaceutical Inc. (RARE) announced the accelerated FDA approval of Genglycos, its first gene therapy, for Glycogen Storage Disease Type Ia (GSDIa). This is a major pos…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 95
Ultragenyx Pharmaceutical shares are trading higher after the company announced that the FDA granted accelerated approval for GENGLYCOS. Also, Cantor Fitzgerald maintained an Overweight rating on the stock and raised its price target from $96 to $103.
The FDA's accelerated approval of GENGLYCOS is a major positive catalyst for Ultragenyx Pharmaceutical (RARE), significantly de-risking the drug's commercialization path and openin…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $103
Cantor Fitzgerald analyst Kristen Kluska maintained an 'Overweight' rating on Ultragenyx Pharmaceutical (RARE) and raised the price target from $96 to $103. This action signals con…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 95
Ultragenyx Pharmaceutical Obtains FDA Accelerated Approval For GENGLYCOS In Adult And Pediatric Patients Eight Years And Older With Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical (RARE) has received accelerated FDA approval for GENGLYCOS, a gene therapy for Glycogen Storage Disease Type Ia (GSDIa). This is a major positive catalyst…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 85
Ultragenyx Pharmaceutical shares are trading higher after the company reported better-than-expected Q2 financial results. Also, the company reaffirmed its FY2026 sales guidance.
This headline represents a significant positive corporate catalyst for Ultragenyx Pharmaceutical. Better-than-expected earnings demonstrate strong operational execution, while reaf…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 55
Ultragenyx Pharmaceutical Affirms FY2026 Sales Guidance of $730.000M-$760.000M vs $746.958M Est
Ultragenyx Pharmaceutical filed an 8-K to affirm its FY2026 sales guidance, keeping it unchanged at $730 million to $760 million. This is a routine disclosure that confirms the com…
Jul 29, 2026
Energy/Commodity
Neutral
Impact 75
Rare Earths Americas Announces Foothills Rare Earths District In Georgia, 17.5 Times Larger Than Shiloh; Plans $15M Exploration Investment In 2026
This news is a significant development for the rare earths sector, potentially shifting supply chain dynamics. The announcement of a district 17.5 times larger than Shiloh, coupled…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.